TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Chronic Care Model Based QI Program to Improve the Care of Patients With CKD
Brief Summary: The goal of this study is to evaluate the impact of a chronic care model (CCM) based quality improvement program on 1) outcomes for patients with chronic kidney disease (CKD) and 2) adherence to CKD guidelines. This pilot study will evaluate the feasibility of a CCM based quality improvement program for patients with CKD and assess potential mechanisms for the intervention's effect.

Hypothesis: Implementing a CCM based quality improvement program including system level support in the form of collaborative care, a CKD registry, and provider education will 1) reduce systolic BP in patients with poorly controlled hypertension, 2) increase the percentage of patients appropriately monitored for metabolic complications, and 3) decrease the rate of catheter use in patients initiating dialysis.


Options:
A: Arm Label: Lifestyle behavior intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle behavior interventon grop | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Placebo Comparator: Control group | Intervention Type: BEHAVIORAL; Name: Lifestyle behavior interventon grop; Assigned to Arm(s): Lifestyle behavior intervention group | Intervention Type: OTHER; Name: Placebo Comparator: Control group; Assigned to Arm(s): Control group
B: Arm Label: Life Style counseling (Star-Mama); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Life Style Counseling (Star-Mama) | Arm Label: Educational Resource Support; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Life Style Counseling (Star-Mama); Assigned to Arm(s): Life Style counseling (Star-Mama)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: remote simultaneous medical interpreting | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: usual and customary | Arm Label: 3; Type: OTHER; Interventions: Other: ENglish speaking | Intervention Type: OTHER; Name: remote simultaneous medical interpreting; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: usual and customary; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: ENglish speaking; Assigned to Arm(s): 3
D: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Chronic Care Model Based QI Program to Improve the Care of Patients With CKD
Brief Summary: The goal of this study is to evaluate the impact of a chronic care model (CCM) based quality improvement program on 1) outcomes for patients with chronic kidney disease (CKD) and 2) adherence to CKD guidelines. This pilot study will evaluate the feasibility of a CCM based quality improvement program for patients with CKD and assess potential mechanisms for the intervention's effect.

Hypothesis: Implementing a CCM based quality improvement program including system level support in the form of collaborative care, a CKD registry, and provider education will 1) reduce systolic BP in patients with poorly controlled hypertension, 2) increase the percentage of patients appropriately monitored for metabolic complications, and 3) decrease the rate of catheter use in patients initiating dialysis.


Options:
A: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Complex tailored intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Complex tailored intervention | Intervention Type: BEHAVIORAL; Name: Complex tailored intervention; Assigned to Arm(s): Complex tailored intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care
C: Arm Label: Pharmacist-Physician Collaborative Medication Management; Type: EXPERIMENTAL; Interventions: Other: Pharmacist-Physician Collaborative Medication Therapy Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist-Physician Collaborative Medication Therapy Management; Assigned to Arm(s): Pharmacist-Physician Collaborative Medication Management
D: Arm Label: Interactive SMS; Type: EXPERIMENTAL; Interventions: Other: Interactive SMS | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Interactive SMS; Assigned to Arm(s): Interactive SMS | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Chronic Care Model Based QI Program to Improve the Care of Patients With CKD
Brief Summary: The goal of this study is to evaluate the impact of a chronic care model (CCM) based quality improvement program on 1) outcomes for patients with chronic kidney disease (CKD) and 2) adherence to CKD guidelines. This pilot study will evaluate the feasibility of a CCM based quality improvement program for patients with CKD and assess potential mechanisms for the intervention's effect.

Hypothesis: Implementing a CCM based quality improvement program including system level support in the form of collaborative care, a CKD registry, and provider education will 1) reduce systolic BP in patients with poorly controlled hypertension, 2) increase the percentage of patients appropriately monitored for metabolic complications, and 3) decrease the rate of catheter use in patients initiating dialysis.


Options:
A: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Interventions for Dialysis Facilities | Intervention Type: BEHAVIORAL; Name: Behavioral Interventions for Dialysis Facilities; Assigned to Arm(s): Behavioral Intervention
C: Arm Label: Inform Me: web-based education tool; Type: EXPERIMENTAL; Interventions: Behavioral: Inform Me: web-based education tool | Arm Label: Control Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Inform Me: web-based education tool; Assigned to Arm(s): Inform Me: web-based education tool
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: automated clinical alerts, Other: provider education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: provider education | Intervention Type: OTHER; Name: automated clinical alerts; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: provider education; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Chronic Care Model Based QI Program to Improve the Care of Patients With CKD
Brief Summary: The goal of this study is to evaluate the impact of a chronic care model (CCM) based quality improvement program on 1) outcomes for patients with chronic kidney disease (CKD) and 2) adherence to CKD guidelines. This pilot study will evaluate the feasibility of a CCM based quality improvement program for patients with CKD and assess potential mechanisms for the intervention's effect.

Hypothesis: Implementing a CCM based quality improvement program including system level support in the form of collaborative care, a CKD registry, and provider education will 1) reduce systolic BP in patients with poorly controlled hypertension, 2) increase the percentage of patients appropriately monitored for metabolic complications, and 3) decrease the rate of catheter use in patients initiating dialysis.


Options:
A: Arm Label: Symptom management nurse intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom management nurse intervention | Arm Label: Feedback intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Feedback intervention | Intervention Type: BEHAVIORAL; Name: Symptom management nurse intervention; Assigned to Arm(s): Symptom management nurse intervention | Intervention Type: BEHAVIORAL; Name: Feedback intervention; Assigned to Arm(s): Feedback intervention
B: Arm Label: Group Based; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based (GB) Intervention | Arm Label: Home-Based; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home-Based (HB) Intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group-Based (GB) Intervention; Assigned to Arm(s): Group Based | Intervention Type: BEHAVIORAL; Name: Home-Based (HB) Intervention; Assigned to Arm(s): Home-Based
C: Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction; Assigned to Arm(s): N/A
D: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dry Needling Versus Strain Counterstrain Technique: Pilot Study Comparing Effects Over the Upper Trapezius Myofascial Trigger Point
Brief Summary: This study investigates the effect of two different techniques (dry needling and Strain-counterstrain manual technique) on the upper trapezius myofascial trigger point (MTP). Subjects with active or latent MTP in this location of the muscle will be identified and will be randomly assigned to one out of three groups: dry needling, strain-counterstrain or placebo manual technique. Pain pressure threshold, provoked pain, pain at rest, neck disability and electromyography (EMG) activity of the upper trapezius will be registered before and after six sessions of treatment.


Options:
A: Arm Label: Dry Needling of trigger point; Type: EXPERIMENTAL; Interventions: Other: Dry needling | Arm Label: Strain-counterstraing technique; Type: EXPERIMENTAL; Interventions: Other: Strain-counterstrain technique | Arm Label: Placebo manual technique; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo manual technique | Intervention Type: OTHER; Name: Dry needling; Assigned to Arm(s): Dry Needling of trigger point | Intervention Type: OTHER; Name: Strain-counterstrain technique; Assigned to Arm(s): Strain-counterstraing technique | Intervention Type: OTHER; Name: Placebo manual technique; Assigned to Arm(s): Placebo manual technique
B: Arm Label: Group I Experimental: thoracic manipulation; Type: EXPERIMENTAL; Interventions: Other: Thoracic manipulation | Arm Label: Group II Control; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional pt protocol | Intervention Type: OTHER; Name: Thoracic manipulation; Assigned to Arm(s): Group I Experimental: thoracic manipulation | Intervention Type: OTHER; Name: conventional pt protocol; Assigned to Arm(s): Group II Control
C: Arm Label: cupping massage; Type: EXPERIMENTAL; Interventions: Procedure: cupping massage | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Progressive muscle relaxation | Intervention Type: PROCEDURE; Name: cupping massage; Assigned to Arm(s): cupping massage | Intervention Type: PROCEDURE; Name: Progressive muscle relaxation; Assigned to Arm(s): control group
D: Arm Label: Post Isometric Relaxation; Type: EXPERIMENTAL; Interventions: Other: 1.Post Isometric Relaxation | Arm Label: Myofascial Release Therapy; Type: EXPERIMENTAL; Interventions: Other: 1.Myofascial Release therapy | Intervention Type: OTHER; Name: 1.Post Isometric Relaxation; Assigned to Arm(s): Post Isometric Relaxation | Intervention Type: OTHER; Name: 1.Myofascial Release therapy; Assigned to Arm(s): Myofascial Release Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Blacks and Exacerbations on LABA vs. Tiotropium (BELT)
Brief Summary: We are doing this study to learn how genes affect the way that people, specifically Black people, respond to treatment for asthma. Recent studies suggest that people respond differently to some asthma medications (eg Serevent, Foradil). Some people feel better when they use these inhalers, but others may not, and some people get worse. It seems that this difference shows up more often in Blacks than in Whites, which is why we are looking for Black subjects for this study. In all people, this difference seems to depend on their genes or DNA. This study is comparing the use of long acting asthma medications (Serevent, Foradil) to Tiotropium (Spiriva) for the treatment of asthma. Spiriva is used to treat chronic obstructive pulmonary disease (COPD). This study will help to see if this medication is also useful for treating asthma and whether it works better for some people than the current asthma medications.


Options:
A: Arm Label: Tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium | Arm Label: Salmeterol or Formoterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Formoterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol or Formoterol | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Salmeterol or Formoterol
B: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol xinafoate; Assigned to Arm(s): N/A
C: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: tiotropium 2.5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 1.25 mcg (2 actuations/day) | Arm Label: tiotropium 18 mcg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium 18 mcg | Arm Label: tiotropium 5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg (2 actuations/day) | Intervention Type: DRUG; Name: tiotropium 18 mcg; Assigned to Arm(s): tiotropium 18 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 1.25 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 2.5 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 5 mcg and placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome
Brief Summary: The purpose of this study is to determine whether vardenafil is effective in improving clinical symptoms and peripheral blood flow in patients with primary and secondary Raynaud phenomenon.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tadalafil | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): Placebo
B: Arm Label: Vardenafil 10 mg bid; Type: EXPERIMENTAL; Interventions: Drug: vardenafil, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: vardenafil, Drug: Placebo | Intervention Type: DRUG; Name: vardenafil; Assigned to Arm(s): Placebo, Vardenafil 10 mg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Vardenafil 10 mg bid
C: Arm Label: Sildenafil 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil 80 mg | Arm Label: Sildenafil 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil 40 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil 40 mg; Assigned to Arm(s): Sildenafil 40 mg | Intervention Type: DRUG; Name: Sildenafil 80 mg; Assigned to Arm(s): Sildenafil 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Amlodipine-Udenafil (AU) arm; Type: EXPERIMENTAL; Interventions: Drug: Udenafil or Amlodipine | Arm Label: Udenafil-Amlodipine (UA) arm; Type: EXPERIMENTAL; Interventions: Drug: Udenafil or Amlodipine | Intervention Type: DRUG; Name: Udenafil or Amlodipine; Assigned to Arm(s): Amlodipine-Udenafil (AU) arm, Udenafil-Amlodipine (UA) arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension
Brief Summary: The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone Palmitate | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Paliperidone Palmitate; Assigned to Arm(s): 001
B: Arm Label: Iloperidone; Type: EXPERIMENTAL; Interventions: Drug: Iloperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Iloperidone; Assigned to Arm(s): Iloperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Risperidone 4.0 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1.5 mg, Cariprazine 3.0 mg, Cariprazine 4.5 mg | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone 4.0 mg
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: paliperidone palmitate | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): 001

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension
Brief Summary: The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia


Options:
A: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A
B: Arm Label: 10 milligrams (mg) LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 milligrams (mg) LY2140023, 160 mg LY2140023, 80 mg LY2140023 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MK-0777 8 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: MK-0777 3 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 8 mg | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 3 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Iloperidone; Type: EXPERIMENTAL; Interventions: Drug: Iloperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Iloperidone; Assigned to Arm(s): Iloperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D